Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels

Overview

Journal Front Pharmacol

Date 2020 Jun 2

PMID 32477111

Citations 2

Authors

Aly A M Shaalan

Mohamed El-Sherbiny

Taghrid B El-Abaseri

Mohamed Z Shoaeir

Tarek M Abdel-Aziz

Magda I Mohamed

Sawsan A Zaitone

Hala M F Mohammad

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Rabeprazole, a proton pump inhibitor (PPIs) is much endorsed to patients with increased gastric acidity. PPIs were accused to have osteoporotic effects on patients who chronically use them. The point of the current investigation was to decide the impact of rabeprazole on osteoporosis and to explore the modulatory effects of dietary calcium or alendronate on this side effect.

Methods: 80 female mice were alienated into four groups maintained for 18 weeks: [1] Vehicle group: given distilled water in 12 ml/kg, P.O. [2] Rabeprazole control group: given rabeprazole in a dose equals 10 mg/kg every 48 h, P.O. [3] Rabeprazole + calcium: given rabeprazole (10 mg/kg every 48 h) along with calcium supplement. [4] Rabeprazole + alendronate: given rabeprazole (10 mg/kg every 48 h) and alendronate (1 mg/kg per week, i.p.). Serum calcium, phosphorus and parathyroid hormone were measured. Both femurs were kept in paraformaldehyde, and then the right one was used for X-ray examination with analysis by Digora software and the left one for histopathological examination (H&E) and immunohistochemical stains for osteopontin and tartrate resistant acid phosphatase (TRAP).

Results: Calcium supplementation or administration of alendronate along with rabeprazole significantly restored the mean bone density as shown by X-ray analysis. Femurs from mice received rabeprazole showed widely separated, thin-walled bone trabeculae and increased number of osteoclasts. Calcium or alendronate with rabeprazole showed thick bone trabeculae without full recovery from rabeprazole induced damage. Adding calcium supplementation to rabeprazole did not affect the histological abnormalities related to osteoclasts meanwhile alendronate produced inactivation of osteoclasts. Both calcium and alendronate decreased the rabeprazole-induced increment in the femur osteopontin level.

Conclusion: Calcium or alendronate can be recommended for female patients on PPI therapy who are at risk of osteopenia.

Citing Articles

Preparation, Structural Characterization, and Stability of Low-Molecular-Weight Collagen Peptides-Calcium Chelate Derived from Tuna Bones.

Zhong Y, Zhou Y, Ma M, Zhao Y, Xiang X, Shu C Foods. 2023; 12(18).

PMID: 37761111 PMC: 10530123. DOI: 10.3390/foods12183403.

Aerobic Physical Exercise as a Non-medical Intervention for Brain Dysfunction: State of the Art and Beyond.

Jia Y, Yao Y, Zhuo L, Chen X, Yan C, Ji Y Front Neurol. 2022; 13:862078.

PMID: 35645958 PMC: 9136296. DOI: 10.3389/fneur.2022.862078.

References

Nagai T, Imai H, Honda S, Negi A . Antiangiogenic effects of bisphosphonates on laser-induced choroidal neovascularization in mice. Invest Ophthalmol Vis Sci. 2007; 48(12):5716-21. DOI: 10.1167/iovs.07-1023. View

Kaye J, Jick H . Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28(8):951-9. DOI: 10.1592/phco.28.8.951. View

CONNERTY H, BRIGGS A . Determination of serum calcium by means of orthocresolphthalein complexone. Am J Clin Pathol. 1966; 45(3):290-6. DOI: 10.1093/ajcp/45.3.290. View

Savarino E, Pohl D, Zentilin P, Dulbecco P, Sammito G, Sconfienza L . Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut. 2009; 58(9):1185-91. PMC: 2719081. DOI: 10.1136/gut.2008.175810. View

Parikh N, Howden C . The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am. 2010; 39(3):529-42. PMC: 3117659. DOI: 10.1016/j.gtc.2010.08.009. View

Corley D, Kubo A, Zhao W, Quesenberry C . Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010; 139(1):93-101. PMC: 2902649. DOI: 10.1053/j.gastro.2010.03.055. View

Hotta H, Kon S, Katagiri Y, Tosa N, Tsukamoto T, Chambers A . Detection of various epitopes of murine osteopontin by monoclonal antibodies. Biochem Biophys Res Commun. 1999; 257(1):6-11. DOI: 10.1006/bbrc.1999.0412. View

Ramirez E, Lei S, Borobia A, Pinana E, Fudio S, Munoz R . Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010; 5(4):288-97. DOI: 10.2174/157488410793352067. View

Nehra A, Alexander J, Loftus C, Nehra V . Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018; 93(2):240-246. DOI: 10.1016/j.mayocp.2017.10.022. View

10.

Ishijima M, Tsuji K, Rittling S, Yamashita T, Kurosawa H, Denhardt D . Resistance to unloading-induced three-dimensional bone loss in osteopontin-deficient mice. J Bone Miner Res. 2002; 17(4):661-7. DOI: 10.1359/jbmr.2002.17.4.661. View

11.

Chesnut 3rd C, Harris S . Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporos Int. 1993; 3 Suppl 3:S17-9. DOI: 10.1007/BF01623003. View

12.

Wei Q, Huang L, Tan X, Chen Z, Chen S, Deng W . Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women. Scand J Clin Lab Invest. 2015; 76(1):33-9. DOI: 10.3109/00365513.2015.1087045. View

13.

Sheraly A, Lickorish D, Sarraf F, Davies J . Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv. 2009; 6(2):192-8. DOI: 10.2174/156720109787846225. View

14.

Krause M, Keller J, Beil B, van Driel I, Zustin J, Barvencik F . Calcium gluconate supplementation is effective to balance calcium homeostasis in patients with gastrectomy. Osteoporos Int. 2014; 26(3):987-95. DOI: 10.1007/s00198-014-2965-1. View

15.

Gorgels T, Waarsing J, de Wolf A, Ten Brink J, Loves W, Bergen A . Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticum. J Mol Med (Berl). 2010; 88(5):467-75. PMC: 2859158. DOI: 10.1007/s00109-010-0596-3. View

16.

Gulley J, Wu S, Arlen P, Dahut W . Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer. 2007; 5(6):403-5. DOI: 10.3816/CGC.2007.n.025. View

17.

Liu J, Li X, Fan L, Yang J, Wang J, Sun J . Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis. Life Sci. 2019; 218:213-223. DOI: 10.1016/j.lfs.2018.12.058. View

18.

Boanini E, Torricelli P, Forte L, Pagani S, Mihailescu N, Ristoscu C . Antiresorption implant coatings based on calcium alendronate and octacalcium phosphate deposited by matrix assisted pulsed laser evaporation. Colloids Surf B Biointerfaces. 2015; 136:449-56. DOI: 10.1016/j.colsurfb.2015.09.044. View

19.

Saag K, Shane E, Boonen S, Marin F, Donley D, Taylor K . Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20):2028-39. DOI: 10.1056/NEJMoa071408. View

20.

Pham C, Regal R, Bostwick T, Knauf K . Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006; 40(7-8):1261-6. DOI: 10.1345/aph.1G703. View